Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EPS (Weighted Average and Diluted) (2020 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.69 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 87.41% year-over-year to -$0.69, compared with a TTM value of -$4.48 through Sep 2025, down 2047.83%, and an annual FY2024 reading of -$0.19, up 66.67% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.69 for Q3 2025 at X4 Pharmaceuticals, up from -$3.63 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $13.57 in Q2 2024 and bottomed at -$7.77 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.49, with a median of -$0.33 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 4212.12% in 2024, while the deepest fall reached 54700.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.28 in 2021, then surged by 104.69% to $0.06 in 2022, then crashed by 250.0% to -$0.09 in 2023, then crashed by 122.22% to -$0.2 in 2024, then crashed by 245.0% to -$0.69 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for XFOR at -$0.69 in Q3 2025, -$3.63 in Q2 2025, and $0.04 in Q1 2025.